The response-to-retention hypothesis of early atherogenesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 5, 1995, Pages 551-562

  Williams, Kevin Jon ^a   Tabas, Ira ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN;

ANIMAL; ARTERIOSCLEROSIS; ARTERY; BIOLOGICAL MODEL; HUMAN; METABOLISM; REVIEW;

ANIMAL; ARTERIES; ARTERIOSCLEROSIS; HUMAN; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; PROTEOGLYCANS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029299438     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.atv.15.5.551     Document Type: Review

References (240)

1. Faber M. The human aorta: sulfate-containing polyuronides and the deposition of cholesterol. Arch Pathol. 1949;48:342-350.
2. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res. 1974;12:1-49.
3. Srinivasan SR, Radhakrishnamurthy B, Vijayagopal P, Berenson GS. Proteoglycans, lipoproteins, and atherosclerosis. Adv Exp Med Biol. 1991;285:373-381.
4. Simionescu N, Sima A, Dobrian A, Tirziu D, Simionescu M. Pathobiochemical changes of the arterial wall at the inception of atherosclerosis. Curr Top Pathol. 1993;87:1-45.
5. Wissler RW. Morphological characteristics of the developing atherosclerotic plaque: animal studies and studies of lesions from young people. Atheroscler Rev. 1991;23:91-103.
6. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994;14:840-856.
7. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:369-377.
8. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:420-425.
9. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol. 1977;86:675-684.
10. DiCorleto PE, Chisolm GM. Participation of the endothelium in the development of the atherosclerotic plaque. Prog Lipid Res. 1986;25:365-374.
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
12. DiCorleto PE, Soyombo AA. The role of the endothelium in atherogenesis. Curr Opin Lipidol. 1993;4:364-372.
13. Taylor KE, Glagov S, Zarins CK. Preservation and structural adaptation of endothelium over experimental foam cell lesions: quantitative ultrastructural study. Arteriosclerosis. 1989;9:881-894.
14. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human atherosclerosis, III: immunocytochemical analysis of the cell composition of lesions of young adults. Am J Pathol. 1992;140:907-914.
15. Simionescu N, Mora R, Vasile E, Lupu F, Filip DA, Simionescu M. Prelesional modifications of the vessel wall in hyperlipidemic atherogenesis: extracellular accumulation of modified and reassembled lipoproteins. Ann NY Acad Sci. 1990;598:1-16.
16. Minick CR, Stemerman MG, Insull W Jr. Effect of regenerated endothelium on lipid accumulation in the arterial wall. Proc Natl Acad Sci U S A. 1977;74:1724-1728.
17. 125I-labeled LDL accumulation in the healing, balloon-deendothelialized rabbit aorta. Arterioscler Thromb. 1992;12:1088-1098.
18. Davies PF, Robotewskyj A, Griem ML, Dull RO, Polacek DC. Hemodynamic forces and vascular cell communication in arteries. Arch Pathol Lab Med. 1992;116:1301-1306.
19. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
20. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med. 1992;116:1292-1300.
21. McGill HC, Geer JC, Holman RL. Sites of vascular vulnerability in dogs demonstrated by Evans blue. Arch Pathol. 1957;64:303-311.
22. Ross R, Masuda J, Raines EW. Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. Ann NY Acad Sci. 1990;598:102-112.
23. Nielsen LB, Nordestgaard BG, Stender S, Kjeldsen K. Aortic permeability to LDL as a predictor of aortic cholesterol accumulation in cholesterol-fed rabbits. Arterioscler Thromb. 1992;12:1402-1409.
24. Thubrikar MJ, Keller AC, Holloway PW, Nolan SP. Distribution of low density lipoprotein in the branch and non-branch regions of the aorta. Atherosclerosis. 1992;97:1-9.
25. 125I-LDL, and parenteral Evans blue dye protein complex along the aortas of normocholesterolemic minipigs as predictors of subsequent hypercholesterolemic atherogenesis. Arterioscler Thromb. 1993;13:1193-1204.
26. Herrmann RA, Malinauskas RA, Truskey GA. Characterization of sites with elevated LDL permeability at intercostal, celiac, and iliac branches of the normal rabbit aorta. Arterioscler Thromb. 1994;14:313-323.
27. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol. 1994;5:252-257.
28. Anitschkow N, Chalatow S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zentralbl Allg Pathol. 1913;24:1-9.
29. Capron L. Pathogenesis of atherosclerosis: an update on the three main theories. Ann Cardiol Angeiol (Paris). 1989;38:631-634.
30. Hoeg JM, Klimov AN. Cholesterol and atherosclerosis: "the new is the old rediscovered." Am J Cardiol. 1993;72:1071-1072.
31. Vasile E, Simionescu M, Simionescu N. Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J Cell Biol. 1983;96:1677-1689.
32. Navab M, Hough GP, Berliner JA, Frank JA, Fogelman AM, Haberland ME, Edwards PA. Rabbit β-migrating very low density lipoprotein increases endothelial macromolecular transport without altering electrical resistance. J Clin Invest. 1986;78:389-397.
33. Lin S-J, Jan K-M, Weinbaum S, Chien S. Transendothelial transport of low density lipoprotein in association with cell mitosis in rat aorta. Arteriosclerosis. 1989;9:230-236.
34. Carew TE, Pittman RC, Marchand ER, Steinberg D. Measurement in vivo of irreversible degradation of low density lipoprotein in the rabbit aorta: predominance of intimal degradation. Arteriosclerosis. 1984;4:214-224.
35. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, I: focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis. 1989;9:895-907.
36. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, II: selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-918.
37. Schwenke DC, St Clair RW. Influx, efflux, and accumulation of LDL in normal arterial areas and atherosclerotic lesions of white Carneau pigeons with naturally occurring and cholesterol-aggravated aortic atherosclerosis. Arterioscler Thromb. 1993;13:1368-1381.
38. Falcone DJ, Hajjar DP, Minick CR. Lipoprotein and albumin accumulation in reendothelialized and deendothelialized aorta. Am J Pathol. 1984;114:112-120.
39. Spring PM, Hoff HF. LDL accumulation in the grossly normal human iliac bifurcation and common iliac arteries. Exp Mol Pathol. 1989;51:179-185.
40. 125I-tyramine cellobiose-labeled low density lipoprotein is greater in the atherosclerosis-susceptible region of White Carneau pigeon aorta and further enhanced once atherosclerotic lesions develop. Arterioscler Thromb. 1992;12:446-460.
41. Kreuzer J, Lloyd MB, Bok D, Fless GM, Scanu AM, Lusis AJ, Haberland ME. Lipoprotein (a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall. Chem Phys Lipids. 1994;67/68:175-190.
42. Lin S-J, Hong C-Y, Chang M-S, Chiang BN, Chien S. Long-term nicotine exposure increases aortic endothelial cell death and enhances transendothelial macromolecular transport in rats. Arterioscler Thromb. 1992;12:1305-1312.
43. 125I-LDL in an in vitro porcine arterial organ-support system. Arterioscler Thromb. 1992;12:1313-1328.
44. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques: coexpression with intercellular adhesion molecule-1. Am J Pathol. 1994;144:952-961.
45. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993;13:197-204.
46. Nievelstein PFEM, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein: a deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb. 1991;11:1795-1805.
47. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
48. Kim JA, Territo MC, Wayner E, Carlos TM, Parhami F, Smith CW, Haberland ME, Fogelman AM, Berliner JA. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler Thromb. 1994;14:427-433.
49. Chisolm GM. Oxidized lipoproteins and leukocyte-endothelial interactions: growing evidence for multiple mechanisms. Lab Invest. 1993;68:369-371.
50. Zand T, Majno G, Nunnari JJ, Hoffman AH, Savilonis BJ, Mac-Williams B, Joris I. Lipid deposition and intimal stress and strain: a study in rats with aortic stenosis. Am J Pathol. 1991;139:101-113.
51. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell: an endothelial paradigm. Circ Res. 1993;72:239-245.
52. Barbee KA, Davies PF, Lal R. Shear stress-induced reorganization of the surface topography of living endothelial cells imaged by atomic force microscopy. Circ Res. 1994;74:163-171.
53. DePaola N, Gimbrone MA Jr, Davies PF, Dewey CF Jr. Vascular endothelium responds to fluid shear stress gradients. Arterioscler Thromb. 1992;12:1254-1257.
54. Lan Q, Mercurius KO, Davies PF. Stimulation of transcription factors NF kappa B and AP1 in endothelial cells subjected to shear stress. Biochem Biophys Res Commun. 1994;201:950-956.
55. Shen J, Gimbrone MA Jr, Luscinskas FW, Dewey CF Jr. Regulation of adenine nucleotide concentration at endothelium-fluid interface by viscous shear flow. Biophys J. 1993;64:1323-1330.
56. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest. 1994;94:885-891.
57. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A. 1993;90:4591-4595.
58. Mills GL, Taylaur CE. The distribution and composition of serum lipoproteins in eighteen animals. Comp Biochem Physiol [B]. 1971;40:489-501.
59. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
60. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-1893.
61. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
62. Manley G, Hawksworth J. Distribution of mucopolysaccharides in the human vascular tree. Nature. 1965;206:1152-1153.
63. Wight TN, Curwen KD, Litrenta MM, Alonso DR, Minick CR. Effect of endothelium on glycosaminoglycan accumulation in injured rabbit aorta. Am J Pathol. 1983;113:156-164.
64. Hoff HF, Wagner WD. Plasma low density lipoprotein accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycan composition. Atherosclerosis. 1986;61:231-236.
65. Ylä-Herttuala S, Pesonen E, Kaprio E, Rapola J, Soveri T, Viikari J, Savilahti E, Oksanen H, Nikkari T. Effect of repeated endotoxin treatment and hypercholesterolemia on preatherosclerotic lesions in weaned pigs, part II: lipid and glycosaminoglycan analysis of intima and inner media. Atherosclerosis. 1988;72:173-181.
66. Cardoso LE, Mouraõ PA. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL. Arterioscler Thromb. 1994;14:115-124.
67. Chao FF, Amende LM, Blanchette-Mackie EJ, Skarlatos SI, Gamble W, Resau JH, Mergner WT, Kruth HS. Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol. 1988;131:73-83.
68. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986;123:109-125.
69. Ylä-Herttuala S, Solakivi T, Hirvonen J, Laaksonen H, Mottonen M, Pesonen E, Raekallio J, Akerblom HK, Nikkari T. Glycosaminoglycans and apolipoproteins B and A-I in human aortas: chemical and immunological analysis of lesion-free aortas from children and adults. Arteriosclerosis. 1987;7:333-340.
70. Camejo G, Hurt-Camejo E, Bondjers G. Effect of proteoglycans on lipoprotein-cell interactions: possible contribution to atherogenesis. Curr Opin Lipidol. 1990;1:431-436.
71. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol. 1993;4:385-391.
72. Etingin OR, Silverstein RL, Hajjar DP. von Willebrand factor mediates platelet adhesion to virally infected endothelial cells. Proc Natl Acad Sci U S A. 1993;90:5153-5156.
73. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-6373.
74. Chisolm GM. Antioxidants and atherosclerosis: a current assessment. Clin Cardiol. 1991;14(2 suppl 1):I25-I30.
75. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
76. Steinberg D. Antioxidants in the prevention of human atherosclerosis: summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop, September 5-6, 1991, Bethesda, Maryland. Circulation. 1992;85:2337-2344.
77. van Hinsbergh VW, Scheffer M, Havekes L, Kempen HJ. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta. 1986;878:49-64.
78. Halliwell B. Albumin - an important extracellular antioxidant? Biochem Pharmacol. 1988;37:569-571.
79. 2(+)-mediated oxidation of dialyzed plasma: effects on low and high density lipoproteins and cholesteryl ester transfer protein. J Lipid Res. 1991;32:243-250.
80. Kalant N, McCormick S. Inhibition by serum components of oxidation and collagen-binding of low-density lipoprotein. Biochim Biophys Acta. 1992;1128:211-219.
81. (2+)-dependent oxidation of low-density lipoproteins and its sensitivity to superoxide dismutase. Biochim Biophys Acta. 1992;1128:50-57.
82. Dobrian A, Mora R, Simionescu M, Simionescu N. In vitro formation of oxidatively-modified and reassembled human low-density lipoproteins: antioxidant effect of albumin. Biochim Biophys Acta. 1993;1169:12-24.
83. Wagner JR, Motchnik PA, Stocker R, Sies H, Ames BN. The oxidation of blood plasma and low density lipoprotein components by chemically generated singlet oxygen. J Biol Chem. 1993;268:18502-18506.
84. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
85. van Berkel TJ, de Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats: recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem. 1991;266:2282-2289.
86. de Rijke YB, Jurgens G, Hessels EM, Hermann A, van Berkel TJ. In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. J Lipid Res. 1992;33:1315-1325.
87. Chang MY, Lees AM, Lees RS. Low-density lipoprotein modification and arterial wall accumulation in a rabbit model of atherosclerosis. Biochemistry. 1993;32:8518-8524.
88. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem. 1987;262:10098-10103.
89. Sparrow CP, Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res. 1993;34:1219-1228.
90. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437-444.
91. Hurt-Camejo E, Camejo G, Rosengren B, López F, Ahlstrom C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb. 1992;12:569-583.
92. Jürgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb. 1993;13:1689-1699.
93. Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, Fogelman AM. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest. 1991;87:2253-2257.
94. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931.
95. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
96. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao YS. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl phenyl-enediamine. J Clin Invest. 1992;89:1885-1891.
97. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
98. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
99. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
100. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
101. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-1035.
102. Gaziano JM. Antioxidant vitamins and coronary artery disease risk. Am J Med. 1994;97:3A-18S-3A-21S.
103. Lund G, Beisiegel U, Seeber N, Nikutta P, Hamm CW. Effect of probucol on progression/regression of coronary artery disease. In: Abstracts Submitted to the Council on Arteriosclerosis for the 66th Scientific Sessions of the American Heart Association. Dallas, Tex: American Heart Association Inc; 1993:124.
104. Elinder LS, Walldius G. Antioxidants and atherosclerosis progression: unresolved questions. Curr Opin Lipidol. 1994;5:265-268.
105. Fruebis J, Steinberg D, Dresel HA, Carew TE. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest. 1994;94:392-398.
106. Stalenhoef AFH, Armstrong VW, Humphries S, Schmitz G, Soutar AK, Taskinen M-R. The 16th annual meeting of the European Lipoprotein Club. Arterioscler Thromb. 1994;14:831-837.
107. Mao SJ, Yates MT, Parker RA, Chi EM, Jackson RL. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. Arterioscler Thromb. 1991;11:1266-1275.
108. Mori Y, Wada H, Nagano Y, Deguchi K, Kita T, Shirakawa S. Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis: effect of probucol on coagulation. Thromb Haemost. 1989;61:140-143.
109. Ku G, Doherty NS, Schmidt LF, Jackson RL, Dinerstein RJ. Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties. FASEB J. 1990;4:1645-1653.
110. Steinbrecher UP, Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler Thromb. 1992;12:608-625.
111. Hoff HF, O'Neil J. Extracts of human atherosclerotic lesions can modify low density lipoproteins leading to enhanced uptake by macrophages. Atherosclerosis. 1988;70:29-41.
112. Kahn JA, Glueck CJ. Familial hypobetalipoproteinemia: absence of atherosclerosis in a postmortem study. JAMA. 1978;240:47-48.
113. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
114. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb. 1994;14:1151-1161.
115. Smith EB, Staples EM. Haemostatic factors in human aortic intima. Lancet. 1981;1:1171-1174.
116. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989;86:3847-3851.
117. Cseh K, Karadi I, Rischak K, Szollar L, Janoki G, Jakab L, Romics L. Binding of fibronectin to human lipoproteins. Clin Chim Acta. 1989;182:75-85.
118. Labat-Robert J, Gruber E, Bihari-Varga M. Interaction between fibronectin, proteoglycans and lipoproteins. Int J Biol Macromol. 1990;12:50-54.
119. Ehnholm C, Jauhiainen M, Metso J. Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis. Eur Heart J. 1990;11(suppl E):190-195.
120. Corey JE, Zilversmit DB. Effect of cholesterol feeding on arterial lipolytic activity in the rabbit. Atherosclerosis. 1977;27:201-212.
121. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
122. Williams KJ, Fless GM, Petrie K, Snyder ML, Brocia RW, Swenson TL. Lipoprotein lipase enhances cellular catabolism of lipoprotein(a). Circulation. 1991;84(suppl II):II-566. Abstract.
123. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins: roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem. 1992;267:13284-13292.
124. Rumsey SC, Obunike JC, Arad Y, Deckelbaum RJ, Goldberg IJ. Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. J Clin Invest. 1992;90:1504-1512.
125. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992;90:2013-2021.
126. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem. 1993;268:9369-9375.
127. Tabas I, Li Y, Brocia RW, Xu SW, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix: a possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem. 1993;268:20419-20432.
128. Portman OW, Alexander M. Metabolism of sphingolipids by normal and atherosclerotic aorta of squirrel monkeys. J Lipid Res. 1970;11:23-30.
129. Xu X-X, Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem. 1991;266:24849-24858.
130. Schissel SL, Williams KJ, Tabas I. Sphingomyelinase (SMase)-induced LDL aggregation: mechanism and relevance. Circulation. 1994;90(pt 2):I-403. Abstract.
131. Howard AN, Patelski J, Bowyer DE, Gresham GA. Atherosclerosis induced in hypercholesterolaemic baboons by immunological injury; and the effects of intravenous polyunsaturated phosphatidyl choline. Atherosclerosis. 1971;14:17-29.
132. Jonasson L, Bondjers G, Hansson GK. Lipoprotein lipase in atherosclerosis: its presence in smooth muscle cells and absence from macrophages. J Lipid Res. 1987;28:437-445.
133. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg U, Steinberg D, Witztum JL. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991;88:10143-10147.
134. Ismail NA, Alavi MZ, Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis. 1994;105:79-87.
135. Linden T, Bondjers G, Camejo G, Bergstrand R, Wilhelmsen L, Wiklund O. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest. 1989;19:38-44.
136. Kostner GM, Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J. 1990; 11(suppl E):184-189.
137. Camejo G, Olofsson S-O, Lopez F, Carlsson P, Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis. 1988;8:368-377.
138. Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest. 1992;89:373-380.
139. Williams KJ, Swenson TL, Brocia RW, Rothman VL, Tuszynski GP, Fisher EA. Involvement of the syndecan family of heparan sulfate proteoglycans (HSPGs) in cellular uptake of complexes of lipoprotein lipase (LpL) with lipoproteins. Circulation. 1993; 88(suppl I):I-365. Abstract.
140. Rutledge JC, Goldberg IJ. Lipoprotein lipase (LpL) affects low density lipoprotein (LDL) flux through vascular tissue: evidence that LpL increases LDL accumulation in vascular tissue. J Lipid Res. 1994;35:1152-1160.
141. Renier G, Skamene E, DeSanctis JB, Radzioch D. High macrophage lipoprotein lipase expression and secretion are associated in inbred murine strains with susceptibility to atherosclerosis. Arterioscler Thromb. 1993;13:190-196.
142. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis. 1992;97:171-185.
143. Zambon A, Torres A, Bijvoet S, Gagne C, Moorjani S, Lupien PJ, Hayden MR, Brunzell JD. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet. 1993;341: 1119-1121.
144. Dugi KA, Feuerstein IM, Santamarina-Fojo S, Brewer HB Jr, Hoeg JM. Lipoprotein lipase may contribute to the variant degree of atherosclerosis in homozygous familial hypercholesterolemia. Circulation. 1994;90(pt 2):I-405. Abstract.
145. Ylä-Herttuala S, Sumuvuori H, Karkola K, Mottonen M, Nikkari T. Glycosaminoglycans in normal and atherosclerotic human coronary arteries. Lab Invest. 1986;54:402-407.
146. O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest. 1992;89:1544-1550.
147. Mattsson L, Johansson H, Ottosson M, Bondjers G, Wiklund O. Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. J Clin Invest. 1993;92:1759-1765.
148. O'Brien KD, Deeb SS, Ferguson M, McDonald TO, Allen MD, Alpers CE, Chait A. Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase. Am J Pathol. 1994;144:538-548.
149. Wagner WD, Salisbury GJ, Rowe HA. A proposed structure of chondroitin 6-sulfate proteoglycan of human normal and adjacent atherosclerotic plaque. Arteriosclerosis. 1986;6:407-417.
150. Hoff HF, Morton RE. Lipoproteins containing apo B extracted from human aortas: structure and function. Ann NY Acad Sci. 1985;454:183-194.
151. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocytes/macrophages. Arterioscler Thromb. 1992;12:237-249.
152. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
153. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
154. McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 1993;92:1004-1008.
155. Autio I, Jaakkola O, Solakivi T, Nikkari T. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett. 1990;277:247-249.
156. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 1994;269:3125-3128.
157. Joseph CK, Wright SD, Bornmann WG, Randolph JT, Kumar ER, Bittman R, Liu J, Kolesnick RN. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J Biol Chem. 1994;269:17606-17610.
158. Hurt E, Bondjers G, Camejo G. Interaction of LDL with human arterial proteoglycans stimulates its uptake by human monocyte-derived macrophages. J Lipid Res. 1990;31:443-454.
159. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Human monocyte-derived macrophages bind low-density-lipoprotein-proteoglycan complexes by a receptor different from the low-density-lipoprotein receptor. Biochem J. 1993;289:837-844.
160. 125I-tyramine-cellobiose-LDL in atherosclerotic lesions of the WHHL rabbit. Arterioscler Thromb. 1992;12:985-995.
161. Rosenfeld ME, Tsukada T, Chait A, Bierman EL, Gown AM, Ross R. Fatty streak expansion and maturation in Watanabe heritable hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 1987;7:24-34.
162. Mori N, Yamada N, Ishibashi S, Kawakami M, Takahashi K, Shimano H, Fujisawa M, Takaku F, Murase T. High-cholesterol diet-induced lipoproteins stimulate lipoprotein lipase secretion in cultured rat alveolar macrophages. Biochim Biophys Acta. 1987;922:103-110.
163. Murata Y, Behr SR, Kraemer FB. Regulation of macrophage lipoprotein lipase secretion by the scavenger receptor. Biochim Biophys Acta. 1988;972:17-24.
164. Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1992;89:10370-10374.
165. Falcone DJ, McCaffrey TA, Haimovitz-Friedman A, Vergilio JA, Nicholson AC. Macrophage and foam cell release of matrix-bound growth factors: role of plasminogen activation. J Biol Chem. 1993;268:11951-11958.
166. Katsuda S, Coltrera MD, Ross R, Gown AM. Human atherosclerosis, IV: immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol. 1993;142:1787-1793.
167. Owens RT, Wagner WD. Metabolism and turnover of cell surface-associated heparan sulfate proteoglycan and chondroitin sulfate proteoglycan in normal and cholesterol-enriched macrophages. Arterioscler Thromb. 1991;11:1752-1758.
168. Tertov VV, Orekhov AN, Ryong LH, Smirnov VN. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells. Tissue Cell. 1988;20:849-854.
169. Sachinidis A, Locher R, Steiner A, Mengden T, Vetter W. Effect of low-density lipoprotein on intracellular calcium, intracellular pH and DNA synthesis in cultured vascular smooth muscle cells. J Hypertens Suppl. 1989;7:S116-S117.
170. Martin BM, Gimbrone MA Jr, Unanue ER, Cotran RS. Stimulation of nonlymphoid mesenchymal cell proliferation by a macrophage-derived growth factor. J Immunol. 1981;126:1510-1515.
171. Rennick RE, Campbell JH, Campbell GR. Vascular smooth muscle phenotype and growth behaviour can be influenced by macrophages in vitro. Atherosclerosis. 1988;71:35-43.
172. Merrilees MJ, Campbell JH, Spanidis E, Campbell GR. Glycosaminoglycan synthesis by smooth muscle cells of differing phenotype and their response to endothelial cell conditioned medium. Atherosclerosis. 1990;81:245-254.
173. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993;268:14131-14137.
174. Rosenfeld ME, Butler S, Ord VA, Lipton BA, Dyer CA, Curtiss LK, Palinski W, Witztum JL. Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb. 1993;13:1382-1389.
175. Saxena U, Ferguson E, Bisgaier CL. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J Biol Chem. 1993;268:14812-14819.
176. Dahlén G, Ericson C, Berg K. In vitro studies of the interaction of isolated Lp(a) lipoprotein and other serum lipoproteins with glycosaminoglycans. Clin Genet. 1978;14:36-42.
177. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-1715.
178. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987;330:113-114.
179. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein, II: preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis. 1990;84:173-181.
180. Beisiegel U. Lipoprotein (a) in the arterial wall. Curr Opin Lipidol. 1991;2:317-323.
181. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis. 1988;8:851-857.
182. Bottalico LA, Keesler GA, Fless GM, Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem. 1993;268:8569-8573.
183. Keesler GA, Li Y, Skiba PJ, Fless GM, Tabas I. Macrophage foam cell lipoprotein(a)/apoprotein(a) receptor: cell-surface localization, dependence of induction on new protein synthesis, and ligand specificity. Arterioscler Thromb. 1994;14:1337-1345.
184. Yashiro A, O'Neil J, Hoff HF. Insoluble complex formation of lipoprotein (a) with low density lipoprotein in the presence of calcium ions. J Biol Chem. 1993;268:4709-4715.
185. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
186. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
187. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
188. Loscalzo J, Weinfeld M, Hess GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10:240-245.
189. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459-2465.
190. Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res. 1992;68:223-232.
191. Terres W, Krewitt M, Hamm CW. Effects of lipoprotein(a) on in vitro lysis of whole blood thrombi from healthy volunteers. Thromb Res. 1993;69:479-487.
192. Edelberg J, Pizzo SV. Lipoprotein (a) regulates plasmin generation and inhibition. Chem Phys Lipids. 1994;67/68:363-368.
193. Crouse JR III. Progress in coronary artery disease risk-factor research: what remains to be done? Clin Chem. 1984;30:1125-1127.
194. Järveläinen HT, Kinsella MG, Wight TN, Sandell LJ. Differential expression of small chondroitin/dermatin sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem. 1991;266:23274-23281.
195. Kojima T, Shworak NW, Rosenberg RD. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem. 1992;267:4870-4877.
196. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties. J Biol Chem. 1992;267:20435-20443.
197. Asundi V, Cowan K, Matzura D, Wagner W, Dreher KL. Characterization of extracellular matrix proteoglycan transcripts expressed by vascular smooth muscle cells. Eur J Cell Biol. 1990;52:98-104.
198. Carey DJ, Evans DM, Stahl RC, Asundi VK, Conner KJ, Garbes P, Cizmeci-Smith G. Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan. J Cell Biol. 1992;117:191-201.
199. Asundi VK, Dreher KL. Molecular characterization of vascular smooth muscle decorin: deduced core protein structure and regulation of gene expression. Eur J Cell Biol. 1992;59:314-321.
200. Cizmeci-Smith G, Asundi V, Stahl RC, Teichman LJ, Chernousov M, Cowan K, Carey DJ. Regulated expression of syndecan in vascular smooth muscle cells and cloning of rat syndecan core protein cDNA. J Biol Chem. 1992;267:15729-15736.
201. Cizmeci-Smith G, Stahl RC, Showalter LJ, Carey DJ. Differential expression of transmembrane proteoglycans in vascular smooth muscle cells. J Biol Chem. 1993;268:18740-18747.
202. Nikkari ST, Jarvelainen HT, Wight TN, Ferguson M, Clowes AW. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 1994;144:1348-1356.
203. Eriksson I, Sandback D, Ek B, Lindahl U, Kjellen L. cDNA cloning and sequencing of mouse mastocytoma glucosaminyl N-deacetylase/N-sulfotransferase, an enzyme involved in the bio-synthesis of heparin. J Biol Chem. 1994;269:10438-10443.
204. Orellana A, Hirschberg CB, Wei Z, Swiedler SJ, Ishihara M. Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line. J Biol Chem. 1994;269:2270-2276.
205. Zhang L, Esko JD. Amino acid determinants that drive heparan sulfate assembly in a proteoglycan. J Biol Chem. 1994;269: 19295-19299.
206. Shworak NW, Shirakawa M, Mulligan RC, Rosenberg RD. Characterization of ryudocan glycosaminoglycan acceptor sites. J Biol Chem. 1994;269:21204-21214.
207. Quentin E, Gladen A, Roden L, Kresse H. A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome. Proc Natl Acad Sci U S A. 1990;87:1342-1346.
208. Ishihara M, Guo Y, Wei Z, Yang Z, Swiedler SJ, Orellana A, Hirschberg CB. Regulation of biosynthesis of the basic fibroblast growth factor binding domains of heparan sulfate by heparan sulfate-N-deacetylase/N-sulfotransferase expression. J Biol Chem. 1993;268:20091-20095.
209. Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol. 1994;5:117-125.
210. Shimano H, Yamada N, Ohsuga J, Shimada M, Yazaki Y. Antiatherogenic effect of apolipoprotein E is mediated through enhanced cholesterol efflux in transgenic mice. Circulation. 1993; 88(suppl I):I-421. Abstract.
211. Carew TE, Koschinsky T, Hayes SB, Steinberg D. A mechanism by which high-density lipoproteins may slow the atherogenic process. Lancet. 1976;1:1315-1317.
212. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
213. Pászty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
214. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
215. Klimov AN, Kozhemiakin LA, Pleskov VM, Andreeva LI. Antioxidant effect of high-density lipoproteins in the peroxidation of low-density lipoproteins. Biull Eksp Biol Med. 1987;103: 550-552.
216. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990;31:645-652.
217. 2+-catalyzed oxidation of human low density lipoprotein. FEBS Lett 1989;257:435-438.
218. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
219. Camejo G, Hurt E, Thubrikar M, Bondjers G. Modification of low density lipoprotein association with the arterial intima: a possible environment for the antiatherogenic action of beta-blockers. Circulation. 1991;84(suppl VI):VI-17-VI-22.
220. Stalenhoef AF, Defesche JC, Kleinveld HA, Demacker PN, Kastelein JJ. Decreased resistance against in vitro oxidation of LDL from patients with familial defective apolipoprotein B-100. Arterioscler Thromb. 1994;14:489-493.
221. Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans: the role of charge and sialic acid content. Atherosclerosis. 1985;55:93-105.
222. Tribble DL, van den Berg JJ, Motchnik PA, Ames BN, Lewis DM, Chait A, Krauss RM. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci U S A. 1994; 91:1183-1187.
223. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 1993;143:1551-1559.
224. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
225. Navab M, Liao F, Hough GP, Ross LA, Van Lenten BJ, Rajavashisth TB, Lusis AJ, Laks H, Drinkwater DC, Fogelman AM. Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message. J Clin Invest. 1991;87:1763-1772.
226. Chen J-K, Hoshi H, McKeehan WL. Stimulation of human arterial smooth muscle cell chondroitin sulfate proteoglycan synthesis by transforming growth factor-beta. In Vitro Cell Dev Biol. 1991;27A:6-12.
227. Merrilees MJ, Scott L. Endothelial cell stimulation of smooth muscle glycosaminoglycan synthesis can be accounted for by transforming growth factor beta activity. Atherosclerosis. 1990;81:255-265.
228. Kurihara H, Nakano T, Takasu N, Arita H. Intracellular localization of group II phospholipase A2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation. Biochim Biophys Acta. 1991;1082:285-292.
229. 2. Circulation. 1994;90(pt 2):I-403. Abstract.
230. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein-related protein. Proc Natl Acad Sci U S A. 1991;88:8342-8346.
231. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A. 1989;86:5810-5814.
232. Luoma J, Hiltunen T, Särkioja T, Moestrup SK, Gliemann J, Kodama T, Nikkari T, Ylä-Herttuala S. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest. 1994;93:2014-2021.
233. 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb. 1994;14:1438-1444.
234. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 1994;94:877-884.
235. Kempen HJ, Buytenhek M, Gruber E, Bihari-Varga M. Factor, present in plasma, inhibiting the interaction of low density lipoprotein with arterial proteoglycan. Atherosclerosis. 1989;78:137-144.
236. Wiklund O, Camejo G, Mattsson L, Lopez F, Bondjers G. Cationic polypeptides modulate in vitro association of low density lipoprotein with arterial proteoglycans, fibroblasts, and arterial tissue. Arteriosclerosis. 1990;10:695-702.
237. Cardin AD, Weintraub HR. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9:21-32.
238. Görög P, Born GVR. Nifedipine inhibits accumulation of LDL and cholesterol in the aorta of the normocholesterolemic rabbit. Arterioscler Thromb. 1993;13:637-639.
239. Phair RD. Cellular calcium and atherosclerosis: a brief review. Cell Calcium. 1988;9:275-284.
240. Tilton GD, Buja LM, Bilheimer DW, Apprill P, Ashton J, McNatt J, Kita T, Willerson JT. Failure of a slow channel calcium antagonist, verapamil, to retard atherosclerosis in the Watanabe heritable hyperlipidemic rabbit: an animal model of familial hypercholesterolemia. J Am Coll Cardiol. 1985;6:141-144.